cabergoline
cabergoline is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Cabergoline. Available dosage form: tablet.
Drug details
- Generic Name
- cabergoline
- Brand Names
- Cabergoline
- Application Number
- NDA020664
- Sponsor
- Mylan Pharmaceuticals Inc.
- NDC Codes
- 3
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- CABERGOLINE
Indications and Usage
1 INDICATIONS AND USAGE CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4) ] . CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. ( 1 ) Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions. ( 5.4 )